Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$3.83.

  • Anika Therapeutics' EPS (Weighted Average and Diluted) rose 89.16% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 65.05%. This contributed to the annual value of -$3.83 for FY2024, which is 32.09% up from last year.
  • Anika Therapeutics' EPS (Weighted Average and Diluted) amounted to -$3.83 in FY2024, which was up 32.09% from -$5.64 recorded in FY2023.
  • Anika Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.28 for FY2021, and its period low was -$5.64 during FY2023.
  • In the last 3 years, Anika Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$3.83 in 2024 and averaged -$3.50.
  • In the last 5 years, Anika Therapeutics' EPS (Weighted Average and Diluted) spiked by 116.57% in 2021 and then tumbled by 464.29% in 2022.
  • Anika Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.69 in 2020, then soared by 116.57% to $0.28 in 2021, then plummeted by 464.29% to -$1.02 in 2022, then plummeted by 452.94% to -$5.64 in 2023, then spiked by 32.09% to -$3.83 in 2024.